Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096047 | 0.77 | HMGCR (0.49) | HMGCRALOX5 | |
| SCHEMBL19463882 | 0.70 | HMGCR (0.56) | HMGCRALOX5GABRA1GABRB2 | |
| SCHEMBL5587556 | 0.70 | HMGCR (0.44) | HMGCRALOX5 | |
| SCHEMBL25277526 | 0.69 | CYP1A2 (0.59) | TAAR1TSHR | |
| SCHEMBL20399526 | 0.69 | HMGCR (0.54) | HMGCRALOX5GABRA1GABRB2 | |
| SCHEMBL28502987 | 0.69 | TSHR (0.42) | HMGCRTSHRHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL6233280 | 0.68 | ALOX5 (0.77) | HMGCRTAAR1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL9549980 | 0.68 | TPMT (0.46) | TAAR1ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL25278005 | 0.68 | CYP1A2 (0.57) | TAAR1TSHR | |
| SCHEMBL9549933 | 0.68 | PTGS2 (0.46) | TAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030113275-A1 | Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2003-06-19 | — | — | US | claimed |
| US-20020035299-A1 | Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2002-03-21 | — | — | US | claimed |
| US-20030113275-A1 | Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2003-06-19 | — | — | US | disclosed |
| US-6528041-B2 | Organoleptic | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-03-04 | — | — | US | disclosed |
| US-20020035299-A1 | Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035299-A1 | Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone | ADRA2B, CYP1B1, ADRB1 | HMGCR 365/4885TAAR1 135/4885TSHR 3018/4885 |
| US-20030113275-A1 | Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone | ADRA2B, CYP1B1, ADRB1 | HMGCR 348/4885TAAR1 140/4885TSHR 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.